Cargando…
Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
AIM: To compare capecitabine and oxaliplatin (XELOX) with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. METHODS: Clinical data from 206 patients who received XELOX or S-1 regimens as adjuvant chemotherapy in stage III gastric cancer were collected. Patients were divi...
Autores principales: | Cho, Jang Ho, Lim, Jae Yun, Cho, Jae Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645114/ https://www.ncbi.nlm.nih.gov/pubmed/29040299 http://dx.doi.org/10.1371/journal.pone.0186362 |
Ejemplares similares
-
Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis
por: Jeong, Sang-Ho, et al.
Publicado: (2022) -
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
por: Yu, Yuanyuan, et al.
Publicado: (2021) -
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006) -
Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study
por: Lee, Chang Min, et al.
Publicado: (2020) -
Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)